These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

508 related items for PubMed ID: 2878007

  • 1. Relationship between somatomedin-C and growth hormone levels in acromegaly: basal and dynamic evaluation.
    Oppizzi G, Petroncini MM, Dallabonzana D, Cozzi R, Verde G, Chiodini PG, Liuzzi A.
    J Clin Endocrinol Metab; 1986 Dec; 63(6):1348-53. PubMed ID: 2878007
    [Abstract] [Full Text] [Related]

  • 2. Plasma insulin-like growth factor-I/somatomedin-C in acromegaly: correlation with the degree of growth hormone hypersecretion.
    Barkan AL, Beitins IZ, Kelch RP.
    J Clin Endocrinol Metab; 1988 Jul; 67(1):69-73. PubMed ID: 2897974
    [Abstract] [Full Text] [Related]

  • 3. Medical treatment of acromegaly with SMS 201-995, a somatostatin analog: a comparison with bromocriptine.
    Chiodini PG, Cozzi R, Dallabonzana D, Oppizzi G, Verde G, Petroncini M, Liuzzi A, del Pozo E.
    J Clin Endocrinol Metab; 1987 Mar; 64(3):447-53. PubMed ID: 2880861
    [Abstract] [Full Text] [Related]

  • 4. Treatment of acromegaly with the long-acting somatostatin analog SMS 201-995.
    Barkan AL, Kelch RP, Hopwood NJ, Beitins IZ.
    J Clin Endocrinol Metab; 1988 Jan; 66(1):16-23. PubMed ID: 2891720
    [Abstract] [Full Text] [Related]

  • 5. SMS 201-995 induces a continuous decline in circulating growth hormone and somatomedin-C levels during therapy of acromegalic patients for over two years.
    Lamberts SW, Uitterlinden P, del Pozo E.
    J Clin Endocrinol Metab; 1987 Oct; 65(4):703-10. PubMed ID: 2888785
    [Abstract] [Full Text] [Related]

  • 6. Changes in growth hormone (GH) secretion induced by human pancreatic GH releasing hormone-44 in acromegaly: a comparison with thyrotropin-releasing hormone and bromocriptine.
    Chiodini PG, Liuzzi A, Dallabonzana D, Oppizzi G, Verde GG.
    J Clin Endocrinol Metab; 1985 Jan; 60(1):48-52. PubMed ID: 3917270
    [Abstract] [Full Text] [Related]

  • 7. Evaluation of selective transsphenoidal adenomectomy by endocrinological testing and somatomedin-C measurement in acromegaly.
    Losa M, Oeckler R, Schopohl J, Müller OA, Alba-Lopez J, von Werder K.
    J Neurosurg; 1989 Apr; 70(4):561-7. PubMed ID: 2647918
    [Abstract] [Full Text] [Related]

  • 8. Long-term treatment of acromegaly with Sandostatin (SMS 201-995). Normalization of most anomalous growth hormone responses.
    Pieters GF, van Liessum PA, Smals AG, van Gennep JA, Benraad TJ, Kloppenborg PW.
    Acta Endocrinol Suppl (Copenh); 1987 Apr; 286():9-18. PubMed ID: 2892339
    [Abstract] [Full Text] [Related]

  • 9. Studies on the response of growth hormone (GH) secretion to GH-releasing hormone, thyrotropin-releasing hormone, gonadotropin-releasing hormone, and somatostatin in acromegaly.
    Shibasaki T, Hotta M, Masuda A, Imaki T, Obara N, Hizuka N, Takano K, Wakabayashi I, Demura H, Ling N.
    J Clin Endocrinol Metab; 1986 Jul; 63(1):167-73. PubMed ID: 2872226
    [Abstract] [Full Text] [Related]

  • 10. A comparison among the growth hormone-lowering effects in acromegaly of the somatostatin analog SMS 201-995, bromocriptine, and the combination of both drugs.
    Lamberts SW, Zweens M, Verschoor L, del Pozo E.
    J Clin Endocrinol Metab; 1986 Jul; 63(1):16-9. PubMed ID: 2872225
    [Abstract] [Full Text] [Related]

  • 11. Investigation of the criteria for assessing the outcome of treatment in acromegaly.
    Lindholm J, Giwercman B, Giwercman A, Astrup J, Bjerre P, Skakkebaek NE.
    Clin Endocrinol (Oxf); 1987 Nov; 27(5):553-62. PubMed ID: 3450453
    [Abstract] [Full Text] [Related]

  • 12. Serum type III procollagen propeptide levels in acromegalic patients.
    Verde GG, Santi I, Chiodini P, Cozzi R, Dallabonzana D, Oppizzi G, Liuzzi A.
    J Clin Endocrinol Metab; 1986 Dec; 63(6):1406-10. PubMed ID: 2878008
    [Abstract] [Full Text] [Related]

  • 13. Value of growth hormone dynamics and somatomedin C (insulin-like growth factor I) levels in predicting the long-term benefit after transsphenoidal surgery for acromegaly.
    Arafah BM, Rosenzweig JL, Fenstermaker R, Salazar R, McBride CE, Selman W.
    J Lab Clin Med; 1987 Mar; 109(3):346-54. PubMed ID: 3102658
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Criteria for the cure of acromegaly: comparison between basal growth hormone and somatomedin C plasma concentrations in active and non-active acromegalic patients.
    Giannella-Neto D, Wajchenberg BL, Mendonça BB, Almeida SF, Macchione M, Spencer EM.
    J Endocrinol Invest; 1988 Jan; 11(1):57-60. PubMed ID: 3361077
    [Abstract] [Full Text] [Related]

  • 16. Paradoxic elevation in serum GH by hypothalamic releasing hormones predicts GH response to acute SMS 201-995 administration.
    Candrina R.
    Recenti Prog Med; 1991 Jan; 82(1):13-6. PubMed ID: 1902962
    [Abstract] [Full Text] [Related]

  • 17. The GH-releasing hormone (GHRH) test in acromegaly before and after adenomectomy.
    Giusti M, Lomeo A, Monachesi M, Mazzocchi G, Attanasio R, Sessarego P, Mignone D, Del Monte P, Giordano G.
    J Endocrinol Invest; 1987 Apr; 10(2):143-51. PubMed ID: 3108356
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Dose-response study and long term effect of the somatostatin analog octreotide in patients with therapy-resistant acromegaly.
    Quabbe HJ, Plöckinger U.
    J Clin Endocrinol Metab; 1989 May; 68(5):873-81. PubMed ID: 2565912
    [Abstract] [Full Text] [Related]

  • 20. [Long-term treatment of acromegaly with the somatostatin analog octreotide (Sandostatin). On the predictive significance of acute tests].
    Schmidt K, Althoff PH, Harris A, Hofmeister-Wagner W, Schifferdecker E, Schöffling K.
    Med Klin (Munich); 1990 Dec 15; 85(12):700-6. PubMed ID: 2128367
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.